Societe Generale Reiterates “$106.00” Price Target for Eli Lilly And Co (LLY)
LLY has been the subject of several other research reports. Credit Suisse Group upgraded shares of Eli Lilly And Co from an underperform rating to a neutral rating in a research report on Wednesday, October 31st. ValuEngine cut shares of Eli Lilly And Co from a buy rating to a hold rating in a report on Tuesday. JPMorgan Chase & Co. set a $123.00 target price on shares of Eli Lilly And Co and gave the stock a buy rating in a report on Friday, October 5th. Bank of America raised their target price on shares of Eli Lilly And Co from $90.00 to $94.00 and gave the stock a neutral rating in a report on Wednesday, July 25th. Finally, Cantor Fitzgerald set a $100.00 target price on shares of Eli Lilly And Co and gave the stock a buy rating in a report on Tuesday, July 24th. Nine research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $111.19.
LLY traded up $2.11 on Wednesday, reaching $112.21. The company had a trading volume of 5,054,447 shares, compared to its average volume of 4,630,530. The firm has a market capitalization of $116.23 billion, a PE ratio of 26.22, a P/E/G ratio of 1.75 and a beta of 0.29. The company has a quick ratio of 1.09, a current ratio of 1.91 and a debt-to-equity ratio of 0.83. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.01%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.
In related news, major shareholder Eli & Co Lilly sold 4,531 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $14.33, for a total transaction of $64,929.23. Following the transaction, the insider now owns 3,934,137 shares of the company’s stock, valued at $56,376,183.21. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 151,793 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $103.23, for a total transaction of $15,669,591.39. Following the transaction, the insider now directly owns 120,555,804 shares in the company, valued at approximately $12,444,975,646.92. The disclosure for this sale can be found here. Insiders sold 1,881,684 shares of company stock valued at $133,274,076 over the last three months. 0.11% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Welch Group LLC bought a new position in Eli Lilly And Co during the third quarter valued at approximately $123,000. Zions Bancorporation bought a new position in shares of Eli Lilly And Co in the third quarter valued at approximately $128,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Eli Lilly And Co in the second quarter valued at approximately $114,000. Legacy Advisors LLC raised its position in shares of Eli Lilly And Co by 118.0% in the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock valued at $116,000 after purchasing an additional 733 shares during the period. Finally, Fort L.P. bought a new position in shares of Eli Lilly And Co in the second quarter valued at approximately $121,000. 76.17% of the stock is currently owned by hedge funds and other institutional investors.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Liquidity
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.